AIR SMOOTH

Brand Owner (click to sort) Address Description
AIRSMOOTH Shenzhen Moore Vaporization Health & Medical Technology Co., Ltd. 401, No. 17, Dongcai Industrial Park, Gushu Town, Baoan District, Shenzhen 518000 China AIR SMOOTH;Cosmetic research; Industrial design services; Material testing; Packaging design; Research and development of new products; Research and development of new products for others; Software as a service (SAAS) services featuring software for analyzing and reporting self-assessment of illness; Technological research in the field of medical cosmetology;
AIRSMOOTH Shenzhen Moore Vaporization Health & Medical Technology Co., Ltd. 401, No. 17, Dongcai Industrial Park, Gushu Town, Baoan District, Shenzhen 518000 China AIR SMOOTH;Humidifiers; Air sterilizers for household purposes; Anion generating humidifiers; Electronic facial steamers; Facial saunas; Heating apparatus for solid, liquid or gaseous fuels; Hot-air space heating apparatus; Steam facial apparatus; Steam generating installations; Steam sterilizers for medical use;
AIRSMOOTH Shenzhen Moore Vaporization Health & Medical Technology Co., Ltd. 401, No. 17, Dongcai Industrial Park, Gushu Town, Baoan District, Shenzhen 518000 China AIR SMOOTH;Fumigation apparatus for medical purposes; Lasers for the cosmetic treatment of the face and skin; Massage apparatus for eyes; Massaging apparatus for personal use; Medical apparatus, namely, electric heating devices for curative treatment; Medical apparatus, namely, respiratory equipment and monitors therefor; Nebulizers for medical purposes; Organoleptic diagnostic testing apparatus for medical, dental or cosmetic use; Skin moisture analyzers for medical purposes; Vaporizers for medical purposes;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. Arterial and venous smooth muscle cells are molecularly distinct from the earliest stages of angiogenesis through to adulthood. This distinction is revealed by expression on arterial cells (e.g., arterial endothelial cells, arterial smooth muscle cells) of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous cells are necessary for angiogenesis. Expression of EphrinB2 in arterial cells (e.g., arterial endothelial cells, arterial smooth muscle cells) can be used to advantage in methods for targeting agents and/or encoded polypeptides to arterial smooth muscle cells, altering angiogenesis, assessing the effect of agents on arterial smooth muscle cells, identifying arterial smooth muscle cells, isolating arterial smooth muscle cells and production of artificial vessels, for example.